Medios

Latest

Calquence tablet formulation approved in the EU for patients with chronic lymphocytic leukaemia
22 febrero 2023
Imfinzi plus Imjudo approved in the EU for patients with advanced liver and non-small cell lung cancers
22 febrero 2023
ReSViNet 2023 data reinforce AstraZeneca’s commitment to help prevent Respiratory Syncytial Virus in infants
21 febrero 2023
AstraZeneca and MSD present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium
16 febrero 2023
Full Year and Q4 2022 results
9 febrero 2023
Forxiga approved in the EU for the treatment of symptomatic chronic heart failure
7 febrero 2023
Tezspire approved for self-administration in the US with a new pre-filled pen
2 febrero 2023
Update on US Food and Drug Administration Emergency Use Authorisation of Evusheld
26 enero 2023
Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
26 enero 2023
Acquisition of Neogene Therapeutics completed
16 enero 2023

Información de contacto

Para contactarse con nosotros dirigirse a:

Nicolás Deantoni
prensaconosur@astrazeneca.com